Cancer powerhouse AstraZeneca rolls the dice on a $75M cash bet on a buzzy upstart in the oncology field – Endpoints News

While lamenting yesterday’s proposed national coverage decision for its controversial Alzheimer’s drug, Biogen’s US president Alisha Alaimo pledged to flood CMS with comments over the next 30 days in an attempt to ensure the final version does not reflect Tuesday’s draft, according to an internal email reviewed by Endpoints News.

“We were prepared for the range of scenarios. Unfortunately, this is one of the most restrictive options CMS could have chosen,” Alaimo said in an email to staff on Wednesday. “If this draft becomes final in April, it will significantly limit Medicare reimbursement for Aduhelm and future therapies in this class.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 128,500+ biopharma pros reading Endpoints daily — and it’s free.

Source link

Scroll to Top